Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enzalutamide + CC-115
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
enzalutamide + CC-115 is a combination therapy investigated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide is a second-generation androgen receptor (AR) signaling inhibitor that blocks androgen binding, nuclear translocation, and DNA binding. CC-115 is an orally bioavailable, dual inhibitor of the mechanistic target of rapamycin (mTOR) complexes 1 and 2 and the DNA-dependent protein kinase (DNA-PK). The combination aims to address resistance mechanisms in prostate cancer, where the PI3K/AKT/mTOR pathway is frequently activated (often via PTEN loss) and compensates for AR inhibition. By simultaneously targeting AR signaling, mTOR-mediated survival pathways, and DNA-PK-mediated DNA repair, the combination seeks to enhance anti-tumor activity and delay the progression of castration-resistant disease.
- Brand names
- Xtandi
- Other names
- Enzalutamide plus CC-115
02
Targets
Mechanistic target of rapamycin kinase complex 2Mechanistic target of rapamycin complex 1AR (Adrenergic receptors)DNA-PK (DNA-dependent protein kinase)
Beyond the preview
Go deeper on enzalutamide + CC-115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enzalutamide + CC-115.